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ApoptosisInduction of apoptosis by TNF has recently been shown to implicate proteases from lysosomal origin, the
cathepsins. Here, we investigated the role in apoptosis of palmitoyl protein thioesterase 1 (PPT1), another
lysosomal enzyme that depalmitoylates proteins. We show that transformed ﬁbroblasts derived from
patients with the infantile form of neuronal ceroid lipofuscinosis (INCL), a neurodegenerative disease due to
deﬁcient activity of PPT1, are partially resistant to TNF-induced cell death (57–75% cell viability vs. 15–30% for
control ﬁbroblasts). TNF-initiated proteolytic cleavage of caspase-8, Bid and caspase-3, as well as cytochrome
c release was strongly attenuated in INCL ﬁbroblasts as compared to control cells. Noteworthy, activation of
p42/p44 mitogen-activated protein kinase and of transcription factor NF-κB by TNF, and induction of cell
death by staurosporine or chemotherapeutic drugs in INCL cells were unaffected by PPT1 deﬁciency.
Resistance to TNF-induced apoptosis was also observed in embryonic ﬁbroblasts derived from Ppt1/Cln1-
deﬁcient mice but not from mice with a targeted deletion of Cln3 or Cln5. Finally, reconstitution of PPT1
activity in mutant cells was accompanied by resensitization to TNF-induced caspase activation and toxicity.
These observations emphasize for the ﬁrst time the role of PPT1 and, likely, protein depalmitoylation in the
regulation of TNF-induced apoptosis.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Considerable advances have been made in the characterization of
the intracellular signaling events emanating from the tumor necrosis
factor (TNF) receptors [1–4]. These receptors are expressed in almost
all cell types and signal both cell death and survival [5,6]. TNFR1
signaling appears to require the sequential formation of two spatially
distinct complexes [7]. The ﬁrst complex, which comprises TNFR1, the
adaptor TRADD, the kinase RIP1 and TRAF2, has been proposed to
promote survival and inﬂammation via the activation of the-7-amido-4-methylcoumarin;
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ll rights reserved.transcription factor NF-κB. The second complex (complex II) involves
TRADD, FADD and procaspase-8 and -10, forms in the cytoplasm and
initiates apoptosis. The balance between apoptotic and proliferative
outcomes could be regulated by TNFRI internalization [8], expression
of anti-apoptotic genes such as the caspase-8 inhibitor FLICE-
inhibitory protein (c-FLIP) or receptor localization to membrane
microdomains [4,9,10].
Besides this two-step model of apoptotic signaling by TNFR1,
there is mounting evidence that this receptor can trigger a lysosome-
dependent death through the action of some lysosomal proteases (for
a recent review, see [11]). Indeed, TNFR1 activation results in acidic
sphingomyelinase-mediated generation of ceramide, which binds
and activates the aspartyl protease cathepsin D by autocatalytic
processing [12]. This would lead to apoptosis via the cleavage of Bid
in the acidic environment of the endolysosomal compartment [13]. In
U937 leukemic cells, TNF-induced cell death was associated with the
release of cathepsin D and cytosol acidiﬁcation [14]. In addition,
involvement of the lysosomal cysteine protease cathepsin B in TNF-
mediated apoptotic signaling has been shown in cathepsin B
knockout hepatocytes that displayed resistance to TNF-induced
mitochondrial release of cytochrome c, caspase activation, and
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from cathepsin B and L-deﬁcient mice appear highly resistant to TNF
[16]. The implication of cathepsin B in apoptosis has also been
reported using TNF-treated tumor cells [17–20]. Finally, the well-
known serine endopeptidase, chymotrypsin B, has been found to be
released from the lysosomes in the cytosol of TNFα-treated rat
hepatoma cells, an event that preceded mitochondrial alterations and
apoptosis [21].
In addition to the implication of cathepsins in apoptosis, another
lysosomal protease, palmitoyl protein thioesterase 1 (PPT1; EC
3.1.2.22) might also be involved in cell death signaling. Over-
expression of PPT1 could protect human neuroblastoma cells against
C2-ceramide-induced caspase-3 activation and DNA fragmentation
[22]. Conversely, PPT1 inhibition increased the susceptibility of these
cells to apoptosis [23]. Moreover, PPT1-deﬁcient lymphoblasts were
more sensitive to apoptosis than control lymphoblasts [24]. PPT1 is
targeted to the lysosome in a mannose 6-phosphate-dependent
manner [25,26] and possesses, at least in vitro, thioesterase activity
against fatty acid thioesters, including palmitoyl-CoA and fatty acid-
modiﬁed proteins, such as H-Ras/p21 [27]. However, its role in the
regulation of S-palmitoylated proteins within cells is not yet
elucidated. Mutations in the CLN1 gene encoding PPT1, located on
chromosome 1p32, result in the infantile form of neuronal ceroid
lipofuscinosis (INCL; MIM256730) [28], a human lysosomal storage
disorder characterized clinically by early visual loss and progressive
neurodegeneration due to a massive neuronal death [29–31]. In mice,
targeted disruption of Ppt1/Cln1 causes a severe neurological
disorder closely resembling human NCL. Neuropathological ﬁndings
include widespread neuronal loss accompanied by glial activation
and apoptosis [32–34].
The present study aimed at investigating the speciﬁc role of PPT1
in TNF-induced apoptosis, by using ﬁbroblasts isolated from patients
affected with INCL. Here, we show that TNF-induced cell death
signaling was strongly inhibited in INCL as compared to control cells.
The same observation was made in Ppt1-deﬁcient murine ﬁbroblasts.
Moreover, correction of the lysosomal enzyme defect in INCL cells
restored their sensitivity to TNF, highlighting the importance of PPT1
in cell death triggered by the cytokine.
2. Materials and methods
2.1. Reagents
Human and murine recombinant TNF and human recombinant
TRAIL were purchased from Peprotech-Tebu (Le-Perray-en-Yvelines,
France). Anti-CD95 was obtained from Immunotech (Marseille,
France). Ac-Asp-Glu-Val-Asp-aminomethylcoumarin (Ac-DEVD-
AMC) was from Bachem (Voisins-Le-Bretonneux, France). DMEM,
trypsin-EDTA, fetal calf serum (FCS), penicillin and streptomycinwere
from Invitrogen (Cergy-Pontoise, France). Other reagents, including 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
and cycloheximide, were from Sigma (Lisle d'Abeau, France).
2.2. Cell lines and transfections
Human SV40 large T-transformed skin ﬁbroblasts derived from
normal individuals or from three INCL patients were obtained as
previously described [35]. Cells from these patients, who all carried
the R151X mutation, were obtained from the laboratory of Dr. S.
Hofmann (University of Texas Southwestern Medical Center, Dallas,
TX) or Dr. O. van Diggelen (Erasmus University, Rotterdam, The
Netherlands), These cells were grown in a humidiﬁed 5% CO2
atmosphere at 37 °C in DMEM medium containing Glutamax
(2 mM), penicillin (100 U/ml), streptomycin (100 μg/ml) and 10%
heat-inactivated FCS. Fibroblasts isolated from one INCL patient were
transfected using Superfect (Quiagen, Courtaboeuf, France) with 5 μgof either pRcCMV or pRcCMV-hPPT1 plasmid (a kind gift from Dr. S.
Hofmann). Transfected cells were then maintained in the presence of
G418 (0.4 mg/ml).
Fibroblasts from Cln1−/−, Cln3−/− and Cln5−/− mice were
obtained from the Department of Molecular Medicine, Helsinki
(Finland). Ppt1/Cln1-deﬁcient cells have an entire deletion of the
Cln1 exon 4 leading to a premature termination codon in exon 3 [33].
In Cln3−/− mice, a deletion of exons 1 to 6 reproduces a knockout
model for juvenile NCL [36]. In Cln5-deﬁcient animals, a model for
Finnish variant late-infantile NCL, exon 3was disrupted by a neomycin
resistance cassette, inducing a frameshift and a premature stop codon
in exon 4 [37]. All the mouse strains were inbred into the C57/BL
genetic background and ﬁbroblasts from C57/BL mice were used as
controls.
2.3. Cytotoxicity assay
Subconﬂuent cells were incubated in DMEM medium containing
1% FCS and cycloheximide in the presence or absence of the indicated
drug or cytokine. Then, cell viability was evaluated by using the
tetrazolium-based MTT assay [38].
2.4. Fluorogenic DEVD cleavage enzyme assay
After incubation with TNF and cycloheximide, cells were sedimen-
ted and washed with PBS. Cell pellets were homogenized in 10 mM
HEPES (pH 7.4), 42 mM KCl, 5 mM MgCl2, 0.5% CHAPS, 1 mM
dithiothreitol, 1 mM PMSF, and 2 μg/ml leupeptin. Reaction mixtures
contained 100 μl of cell lysates and 100 μl of 40 μM Ac-DEVD-AMC.
After 30 min incubation at room temperature, the amount of the
released ﬂuorescent product aminomethylcoumarin was determined
at 351 and 430 nm for the excitation and emission wavelengths,
respectively.
2.5. Release of cytochrome c
After incubation with TNF and cycloheximide, cells were sedimen-
ted and washed with PBS. Cell pellets were resuspended in 5 volumes
of ice-cold homogenization buffer (20 mM HEPES/KOH (pH 7.4),
1 mM EDTA, 0.1% fatty acid-free BSA, 250 mM sucrose, 1 mM
dithiothreitol, 0.1 mM PMSF, 20 μg/ml leupeptin, 10 μg/ml aprotinin
and 10 μg/ml pepstatin A). After swelling for 10 min on ice, cells were
homogenized by 15 strokes of a loose-ﬁtting Dounce homogenizer.
The suspension was then centrifuged at 750 g for 5 min at 4 °C, and
post-nuclear supernatants were centrifuged at 10,000 g for 15 min at
4 °C. Equal amounts of protein were then analyzed by SDS-PAGE (15%
gel) and Western blotting by using 1 μg/ml of anti-cytochrome cmAb
(Becton-Dickinson, Le-Pont-de-Claix, France).
2.6. Western blot analyses
Equal amounts of proteins were separated in a 10 to 15% SDS-
polyacrylamide gel and transferred to a nitrocellulose membrane
(Bio-Rad, Hercules, CA). Proteins were detected using an ECL
detection system (Pierce). Caspase-3 was detected by using a rabbit
polyclonal antiserum given by Dr. D. Nicholson, Merk-Frosst Centre for
Therapeutic Research (Pointe Claire-Dorval, Québec, Canada); cas-
pase-8 with a rabbit polyclonal antiserum given by Dr. M. Peter, The
Ben May Institute for Cancer Research (Chicago, IL); Bid and IκB-α by
using rabbit polyclonal antibodies (Cell Signaling, Le-Perray-en-
Yvelines, France and Santa Cruz Biotechnology, Santa Cruz, CA);
p42/p44 phosphorylated MAPK and Ser32/36-phosphorylated IκB-α
by using a mouse monoclonal antiserum (Cell Signaling). Goat anti-
rabbit and anti-mouse secondary antibodies were from Cell Signaling.
An anti-β-actin (Sigma) or an anti-ERK2 (Santa Cruz-Tebu) was used
as controls for protein loading.
Fig. 1. INCL ﬁbroblasts are partially resistant to TNF-induced cytotoxicity. (A) PPT1
activity in transformed ﬁbroblasts from control subjects (mean of three different cell
lines) or three different INCL patients (means±S.E.M. of 3–9 independent determina-
tions). (B) Control and INCL SV40-transformed ﬁbroblasts were incubated for 16 h in
DMEM medium containing 1% FCS and 50 μg/ml cycloheximide in the presence or
absence of human TNF (50 ng/ml). Cell viability was assessed using the MTT assay, and
is expressed as percentage of the viability of cells treated with cycloheximide only.
Results are means±S.E.M. of 3–7 independent determinations (all in triplicate).
(C) Viability of control (mean of three different cell lines) and INCL1 transformed
ﬁbroblasts that were incubated for 16 h in 1% FCS in the presence of 50 μg/ml
cycloheximide and the indicated concentration of TNF. Results are means±S.E.M. of 3
independent experiments (for the 0.1 and 1 ng/ml TNF concentrations, the error bars in
the control cells are too small to be seen).
Fig. 2. The TNF-induced apoptotic cascade is impaired in INCL ﬁbroblasts. (A) Control
(mean of three different cell lines) and three different INCL transformedﬁbroblastswere
incubated in medium containing 1% FCS with 50 ng/ml human TNF and 50 μg/ml
cycloheximide for the indicated times. Cells were then harvested and DEVDase activity
was determined. Data aremeans±S.E.M. of 3–7 independent experiments. (B) Control1
and INCL1 ﬁbroblasts were treated for the indicated periods with 50 μg/ml
cycloheximide and 50 ng/ml TNF. Cell lysates and cytosolic extracts were prepared as
described in Materials and methods, and analyzed by Western blotting for caspase-8
cleavage, Bid proform disappearance, cytochrome c release, and caspase-3 cleavage. An
anti-β-actin was used as a control for protein loading. Results are representative of 3
independent experiments. Similar results were obtained using the INCL2 cell line.
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PPT1 activity was assayed using 4-methylumbelliferyl-β-D-6-
thiopalmitoyl-glucoside (Moscerdam, Rotterdam, The Netherlands),
as reported [39]. Cell pellets were homogenized in 200 μl distilled
water and brieﬂy sonicated. Reaction mixtures contained 10 μl of cell
lysate and 20 μl of substrate preparation (0.5 mM substrate, 1.5 mM
dithiothreitol and 1 U β-glucosidase). After 1 hour incubation at 37 °C,
the reaction was stopped by adding 2 ml of glycine/NaOH 0.2 M (pH
10.5) buffer. The amount of the released ﬂuorescent product 4-
methylumbelliferone was determined by ﬂuorometry at 358 and
448 nm for the excitation and emission wavelengths, respectively.
Protein concentration was measured with the Bio-Rad dye reagent
using BSA as a standard.
2.8. TNFR1 expression analysis by ﬂow cytometry
TNFR1 expression was analyzed on resting cells. Cells were
detached using PBS containing 10 mM EDTA, sedimented at 4 °C
and washed with PBS. Cells were incubated at 4 °C in the dark for30 min with FITC-conjugated mouse anti-human TNFR1 (R&D
Systems, Lille, France). Isotype control monoclonal antibody (Immu-
notech) was used as a negative control. Cytometric analyses were
performed on a FACScan (Becton-Dickinson) ﬂow cytometer.
2.9. Statistical analyses
Data are presented as means±S.E.M. The Student's t-test was used
for statistical analysis (⁎pb0.05; ⁎⁎pb0.01; ⁎⁎⁎pb0.001 versus
control).
3. Results
3.1. TNF-induced apoptosis of transformed ﬁbroblasts requires PPT1
activity
To evaluate the functional role of PPT1 in TNF-mediated cell death,
we used a genetic model, i.e., SV40-transformed ﬁbroblasts derived
from patients affected with INCL. As compared to ﬁbroblasts derived
from control individuals, PPT1 enzymatic activity in INCL cells was
severely impaired (Fig. 1A). In contrast, the activities of other
lysosomal enzymes (e.g., β-galactosidase and β-hexosaminidase) in
INCL cells were not different from those in controls (data not shown).
The cytotoxic effect of TNF on control cells was dose-dependent (Fig.
1C), leading to a reduction in cell viability of ∼70% after 16 h exposure
to 50 ng/ml TNF (Fig. 1B and C). Under all concentrations tested, INCL
ﬁbroblasts were more resistant to the lethal effect of TNF than their
normal counterparts. This ﬁnding was conﬁrmed on several cell lines
derived from different normal subjects or patients affected with INCL
(Fig. 1B), demonstrating the involvement of PPT1 in TNF-induced
cytotoxicity on human transformed ﬁbroblasts.
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death, the implication of PPT1 in the apoptotic cascade activated by
TNF in INCL transformed ﬁbroblasts was examined. Determination of
the global executioner caspase activity with the ﬂuorogenic tetrapep-
tide substrate Ac-DEVD-AMC, which contains the cleavage site found
in numerous caspase-3 and caspase-7 targets, showed that TNF-
induced caspase processing was strongly inhibited in INCL cells
(Fig. 2A). This effect on caspase-3-like activity was further demon-
strated by Western blot analysis of individual caspases. As illustrated
in Fig. 2B, the cleavage of caspase-3 (i.e., the decrease in the
procaspase form and appearance of cleaved forms) triggered by TNF
was considerably reduced and delayed in INCL cells. TNF treatment of
control cells resulted in cleavage of the initiator caspase-8, which
occurred quite concomitantly to that of effector caspases (Fig. 2B).
This cleavage was accompanied by the complete disappearance of Bid,
a member of the Bcl-2 family known as a substrate of caspase-8, and
the progressive release of cytochrome c into the cytosol. Processing of
both caspase-8 and Bid, as well as the release of cytochrome c were
impaired in PPT1-deﬁcient ﬁbroblasts, further implicating this
enzyme in the apoptotic cascade initiated by TNF with a site of action
likely lying upstream of mitochondria.
3.2. PPT1 is involved in cell death triggered by death receptors but not
receptor-independent cytotoxic agents
To explore further the site of action of PPT1 in the apoptotic
cascade and to test whether PPT1 is involved only in TNF-induced
apoptosis, control andmutant ﬁbroblasts were exposed to TRAIL and a
Fas/CD95 agonist (i.e., an anti-Fas antibody), two members of the TNF
superfamily. These two molecules can induce apoptosis via the death
receptors DR4 or DR5, and Fas/CD95, respectively. As observed upon
TNF stimulation, INCL ﬁbroblasts also resisted signiﬁcantly to TRAILFig. 3. INCL ﬁbroblasts are partially resistant to TRAIL and anti-Fas but not to
staurosporine and chemotherapeutic drugs. (A) Viability of control1 and INCL1
transformed ﬁbroblasts that were incubated for 16 h in the presence of 50 μg/ml
cycloheximide and the indicated concentration of TRAIL or anti-Fas. Cell viability was
assessed using the MTT assay, and is expressed as percentage of the viability of cells
treated with cycloheximide only. Results are means±S.E.M. of 3 independent
determinations (all in triplicate). (B) Control1 and INCL1 transformed ﬁbroblasts were
incubated for 24 h in DMEM medium containing 1% FCS with 100 nM staurosporine,
0.5 μM doxorubicin or 50 μM etoposide. Cell viability was assessed using the MTT assay.
Results are means±S.E.M. of 3–7 independent determinations (all in triplicate).and anti-Fas-mediated apoptosis (Fig. 3A). INCL ﬁbroblasts were then
challenged with the protein kinase inhibitor staurosporine and the
anticancer drugs doxorubicin and etoposide, all stimuli that have been
shown to promote apoptosis by activating the mitochondrial pathway.
Fig. 3B demonstrates that the cytotoxic effects of these agents were
similar in control and INCL cells. These observations suggest that
whereas PPT1 can modulate the apoptotic pathway initiated by
distinct death receptors, it does not affect receptor-independent
cytotoxic signaling.
3.3. TNFR1 expression, and TNF-induced activation of p42/p44 MAPK
and NF-κB do not require a functional PPT1
To test whether the impairment of TNF-induced toxicity in INCL
ﬁbroblasts might be due to an abnormal expression of TNFR1, the cell
surface expression of this receptor was assessed by ﬂow cytometry. Of
note, INCL and normal cells expressed similar levels of TNFR1 at the
plasma membrane (50% versus 41% in INCL and control cells,
respectively) (Fig. 4A).
Ligation of TNFR1 not only signals cell death but also cell survival
and can promote cell proliferation in some situations [2]. To
investigate the role of PPT1 in TNF-induced cell survival signals, we
compared the effects of TNF on p42/p44 MAPK and NF-κB activation
in control and INCL ﬁbroblasts (Fig. 4B). p42/p44 MAPK was found to
be activated as soon as 15 min after exposure to TNF. Both kinetics and
amplitude of p42/p44 MAPK activation were similar in control and
mutant cells. Moreover, TNF elicited IκB phosphorylation and
degradation in INCL as well as in control cells, suggesting that NF-κB
was efﬁciently activated in PPT1-deﬁcient cells. These ﬁndings
indicate that PPT1 is preferentially implicated in the cytotoxic action
of TNF but does not interfere with the cytokine-induced cell survival
signaling.
3.4. Enzymatic correction of INCL ﬁbroblasts restores their sensitivity to
TNF
To establish the role of PPT1 in TNF-mediated cell death, we used
human PPT1-deﬁcient ﬁbroblasts that were stably transfected with a
cDNA encoding human PPT1 (INCL2 PPT) and compared their
response to the lethal effect of TNF with those of parental cells
(INCL2) or mutant cells transfected with the corresponding empty
vector (INCL2 neo). In PPT1-transfected cells, the activity of PPT1 was
increased as compared to that found in mutant or even control
ﬁbroblasts (Fig. 5A). Importantly, expression of PPT1 cDNA in INCL
cells restored the TNF sensitivity (Fig. 5B).
The sensitivity of INCL2 PPT cells was further conﬁrmed by
examining caspase activity. As shown in Fig. 5C, the cleavage of Ac-
DEVD-AMC was signiﬁcantly increased in PPT1-transfected cells
within 2 h, peaking at 6 h post-treatment. No progressive increase
was seen in mutant cells transfected with an empty vector. Moreover,
Western blot analysis demonstrated that executioner caspase-3
processing was enhanced in INCL2 PPT cells, resembling that observed
in normal ﬁbroblasts (see Fig. 2B). Altogether, these data indicate that
in human transformed ﬁbroblasts PPT1 plays a critical role in TNF
apoptotic signaling by regulating effector caspase activation.
3.5. Ppt1-deﬁcient murine ﬁbroblasts also resist TNF-induced killing
In order to consolidate our observations on human cells, we
analyzed the responses to TNF in Ppt1-deﬁcient cells obtained from
transgenic mice with a targeted disruption of the Ppt1/Cln1 gene
[33]. Embryonic ﬁbroblasts from Cln1−/− mice exhibited a deﬁcient
activity of PPT1 (Fig. 6A) and were resistant both to human and
murine TNF-induced cell death (Fig. 6B), indicating that the
impaired pathway is mediated by TNFR1 but not TNFR2 [40]. As
observed in INCL human ﬁbroblasts, the resistance to TNF was
Fig. 4. TNF triggers activation of p42/p44 MAPK and NF-κB equally well in control and INCL ﬁbroblasts. (A) Cell surface expression of TNFR1 in control1 and INCL1 ﬁbroblasts, as
assessed by ﬂow cytometry. The mean ﬂuorescence intensity of gated control and INCL cells was 17.2 and 26.1, respectively; 41% and 50% of the gated cells were positive for TNFR1.
(B) TNF-induced activation of p42/p44 MAPK and NF-κB. Cells were incubated in 1% FCS with or without 50 ng/ml human TNF and 50 μg/ml cycloheximide for the indicated times,
and then harvested. Expression of activated (dually phosphorylated; p-MAPK) or total MAPK (as a loading control), as well as phosphorylated (p-IκBα) and IκBα, was evaluated by
Western blot. Results are representative of 3 independent experiments.
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However, as observed in human cells, TNF-induced activation of
p42/p44 MAPK (Fig. 6D) and NF-κB (data not shown) remained
unaffected in Cln1−/− cells.
3.6. TNF-induced apoptosis is not altered in the CLN3 and CLN5 murine
models of ceroid lipofuscinosis
INCL belongs to the group of neuronal ceroid lipofuscinoses (NCLs)
which comprise different inherited diseases, all characterized by
lysosomal storage of autoﬂuorescent lipopigments and by a neurode-
generative process [41]. In order to test whether the resistance to TNF-
induced apoptosis was a common feature to all ceroid lipofuscinoses,
we analyzed the response to TNF of murine ﬁbroblasts carrying a
deletion in the Cln3 and Cln5 genes responsible for the juvenile and
variant late-infantile forms of NCL, respectively. As illustrated in
Fig. 7A, control, Cln3−/− and Cln5−/− cells were equally sensitive
to the cytotoxic effect of TNF. Moreover, TNF triggered a similar
cleavage of caspase-3 in embryonic ﬁbroblasts from Cln3−/− andCln5−/− mice (Fig. 7B). Thus, the resistance of PPT1-deﬁcient cells
to TNF-induced apoptosis is not a common feature to all forms of NCL.
4. Discussion
Accumulating evidence suggests that in addition to caspases,
lysosomal proteases serve as important mediators in programmed cell
death [11]. This lysosomal pathway of cell death might even be
exacerbated in transformed and immortalized cells [16]. By using
transformed ﬁbroblasts, we show for the ﬁrst time that PPT1, an
enzyme that removes long-chain fatty acids from lipid-modiﬁed
cysteine residues in proteins [42,43], represents one of the lysosomal
regulators of TNF-induced apoptosis. This conclusion is supported by
two lines of evidence. First, both human and murine PPT1-deﬁcient
ﬁbroblasts were more resistant to TNF-induced cytotoxicity than their
normal counterparts. Secondly, reconstitution of PPT1 activity in INCL
cells restored susceptibility to killing. In addition, in other models of
NCL where PPT1 integrity is preserved, such as in Cln3−/− and Cln5
−/− cells, TNF apoptotic signaling was not affected. The participation
Fig. 5. Enzymatic correction of PPT1 activity restores TNF-induced apoptosis in INCL
ﬁbroblasts. (A) PPT1 enzyme activity of control and INCL2 ﬁbroblasts that were
untreated, transfected with the empty vector (INCL2 neo) or the pRcCMV-hPPT1 vector
(INCL2 PPT). Results are representative of 3–9 independent experiments. (B) Cell
viability of control, INCL2, INCL2 neo and INCL2 PPT ﬁbroblasts that were incubated for
16 h in DMEM medium containing 1% FCS and 50 μg/ml cycloheximide in the presence
or absence of human TNF (50 ng/ml). Results are means±S.E.M. of 3–8 independent
determinations (all in triplicate). (C) DEVDase activity in control, INCL2, INCL2 neo and
INCL2 PPT ﬁbroblasts that were incubated in medium containing 1% FCS with 50 ng/ml
TNF and 50 μg/ml cycloheximide for the indicated times. Data aremeans±S.E.M. of 3–4
independent experiments. (D) Analysis of caspase-3 cleavage in INCL2 and INCL2 PPT
ﬁbroblasts treated with 50 ng/ml TNF and 50 μg/ml cycloheximide for the indicated
times. An anti-β-actin was used as a control for protein loading.
Fig. 6. Ppt1/Cln1-deﬁcient murine ﬁbroblasts behave as INCL human ﬁbroblasts with
regard to TNF-induced cytotoxicity. (A) Ppt1 activity in control or Cln1−/− murine
transformed ﬁbroblasts (means±S.E.M. of 3 independent determinations). (B) Control
and Cln1−/−murine ﬁbroblasts were incubated for 16 h in DMEMmedium containing
1% FCS and 10 μg/ml cycloheximide in the presence of the indicated concentration of
human or murine TNF. Cell viability was assessed using the MTT assay, and is expressed
as percentage of the viability of cells treated with cycloheximide only. Results are
means±S.E.M. of 5–7 independent determinations (all in triplicate). (C) Control and
Cln1−/− murine ﬁbroblasts were treated for the indicated periods with 10 μg/ml
cycloheximide and 10 ng/ml of murine TNF. Cell lysates were prepared and analyzed by
Western blotting for caspase-3 cleavage and Bid proform disappearance; β-actin was
used as a loading control. (D) Control and Cln1−/−murine ﬁbroblasts were treated for
the indicated periods with 50 ng/ml of human TNF. Cell lysates were analyzed by
Western blotting for MAPK phosphorylation as in Fig. 4B.
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that caspase activation, cleavage of Bid, and the subsequent release of
mitochondrial cytochrome c, were all signiﬁcantly reduced in PPT1-
deﬁcient ﬁbroblasts. However, other TNF activities than cell death
induction, such as p42/p44 MAPK and NF-κB activation, remained
unaffected in mutant cells, suggesting that PPT1 is not involved in
TNF-induced cell survival signaling.
4.1. Place of PPT1 in TNF-induced apoptosis
Consistent with previous observations that cleavage of Bid, a pro-
apoptotic member of the Bcl-2 family which controls the mitochon-
drial checkpoint of apoptosis, is the most likely route for lysosome-
directed apoptosis [44], the present study suggests that the site of
action of PPT1 lies upstream of mitochondria. The observation that
drugs such as staurosporine induced apoptosis equally well in controland PPT1-deﬁcient cells reinforces the notion that the apoptotic
signaling components at and downstream the mitochondrion are
intact in INCL cells. How PPT1 regulates the apoptotic machinery that
operates downstream of TNFR1 and upstream of mitochondria is still
unclear. PPT1 is a depalmitoylating enzyme that has been reported to
release, in vitro, palmitate from the small GTP-binding proteins,
including p21Ras [43]. Its intracellular physiological substrates,
however, are still unknown.Moreover, despite the lysosomal targeting
of PPT1 [26], its enzymatic activity has a neutral pH optimum, and
extralysosomal localization of PPT1 protein has been reported in
neurons [43,45], suggesting that PPT1 functions might not be limited
to lysosomes [27]. By controlling S-palmitoylation of signaling
proteins, a dynamic process regulating protein function [46–48],
PPT1 could inﬂuence protein distribution between membrane
compartments or subdomains within the same membrane or could
be implicated in protein–protein interactions. For example, some early
steps of TNFR1-mediated signaling, including initiation of apoptosis,
have been reported to take place in caveolae-like domains [9,49–51],
Fig. 7. TNF-induced apoptosis is not altered in other murine models of ceroid
lipofuscinosis. (A) Control, Cln3−/− and Cln5−/− murine transformed ﬁbroblasts
were incubated for 16 h in DMEM medium containing 1% FCS and 10 μg/ml
cycloheximide in the presence of the indicated concentration of human or murine
TNF. Cell viability was assessed using the MTT assay, and is expressed as percentage
of the viability of cells treated with cycloheximide only. Results are means±S.E.M. of
3 independent determinations (all in triplicate). (B) Cln3−/− and Cln5−/− murine
ﬁbroblasts were treated for the indicated periods with 10 μg/ml cycloheximide and
10 ng/ml of murine TNF. Cell lysates were prepared and analyzed by Western
blotting for caspase-3 cleavage; β-actin was used as a loading control. For control
cells, see Fig. 6C.
1256 C. Tardy et al. / Biochimica et Biophysica Acta 1793 (2009) 1250–1258which represent specialized microdomains of the plasma membrane
enriched in sphingolipids, cholesterol [52,53] and several palmitoy-
lated proteins [46]. It is therefore possible that PPT1 regulates
cytokine-induced cell death by affecting protein association within
lipid rafts.
Consistent with this hypothesis, recent ﬁndings demonstrated that
palmitoylation of the death receptor Fas, which belongs to the TNF
superfamily, was essential for its localization into lipid rafts and its
endocytosis [54,55]. Fas palmitoylation appears as a prerequisite to
the apoptotic complex (DISC) assembly into endosomes and the
correct initiation of apoptosis [56]. As reported for Fas, TNF-induced
apoptosis was shown to require also TNF receptor internalization
whereas TNF-triggered survival pathways did not [57]. It is thus
conceivable that, as described for Fas, palmitoylation of TNFR1
inﬂuences its internalization and the subsequent TNF-induced
apoptosis. This hypothesis would be in accordance with our ﬁndings
that PPT1 deﬁciency affects only the TNF-initiated cell death pathway
but not the survival one. Two observations would support this
hypothesis. First, a defect in receptor-mediated endocytosis was
reported in PPT1-deﬁcient ﬁbroblasts [58]. Second, although palmi-
toylation of TNFR1 has not yet been documented, analysis of its
protein sequence reveals the presence of a cysteine residue (Cys248)
that resides just downstream the transmembrane domain, i.e., in an
equivalent site where the palmitoylated cysteine in Fas is found (data
not shown). However, this exciting hypothesis needs detailed
examination to be conﬁrmed.
PPT1 could also inﬂuence lipidic plasma membrane composition.
Recent ﬁndings revealed that PPT1-deﬁcient neurons express an
increased amount of ATP synthase at the plasmamembrane and show
an increased uptake of apolipoprotein A1 [59]. This is associated with
a dysregulated metabolism of cholesterol [60], a major component of
plasma membrane and particularly of lipid rafts. Furthermore, PPT1
was shown to localize into lipid rafts and to regulate their lipid contentin CHO cells [61]. Such modiﬁcations in lipid raft composition may
perturb receptor signaling.
Another possible mode of action of PPT1 in modulating the TNFR1
death signal would be the promotion of complex II formation or the
activation of a factor controlling initiator caspase or Bid cleavage.
Conversely, PPT1 may modulate TNFR1-induced apoptosis by trigger-
ing the depalmitoylation and degradation of an anti-apoptotic
molecule (e.g., cFLIP) or more indirectly that of a factor that regulates
the expression levels of anti-apoptotic molecules. Again, these
hypotheses await further characterization of the PPT1 substrates to
be tested. Alternatively, depalmitoylation of p21Ras by PPT1 may alter
its function [46] and subsequently inﬂuence TNFR1 signaling since Ras
activation has been reported to modulate TNF-induced apoptosis [62].
A further possibility is that the palmitate released by PPT1 is used for
generating a pro-apoptotic messenger, such as ceramide [63].
However, the quantity of palmitate produced by PPT1 is likely to be
insufﬁcient to account for a substantial ceramide generation upon TNF
stimulation, which is considered to occur mostly through sphingo-
myelin hydrolysis [64]. Finally, the possibility that the lysosomal
ceroid storage present in INCL cells somehow affects TNFR1 apoptotic
signal transduction, for instance by impairing release of cathepsins,
cannot be totally excluded.
4.2. Pathophysiology of apoptosis in PPT1 deﬁciency
The major pathological ﬁndings in patients affected with INCL, as
well as Ppt1-deﬁcient mice include accumulation of autoﬂuorescent
lipopigments (GRODs), neuronal loss and glial activation [30,65] but
apoptosis in the cortex and retina have also been reported [29,32]. In
line with the link to apoptotic cell death, overexpression of PPT1 has
been described to protect human neuroblastoma cells from apoptosis
induced by short-chain ceramide or a phosphatidylinositol 3-kinase
inhibitor [22]. Reduction of PPT1 expression in the same cell line by
antisense oligonucleotides enhanced the susceptibility to cell death
[23]. The data of the present study on TNF-induced apoptosis of
transformed ﬁbroblasts and the above ﬁndings may seem at odds.
However, some discrepancies have already been reported regarding
PPT1 processing in neurons and ﬁbroblasts [66]. Furthermore,
whereas PPT1 deﬁciency increased the amount of the F1-ATP
synthase at the plasma membrane of neurons, no similar modiﬁca-
tions were observed in ﬁbroblasts [59]. On the other hand, the nature
of PPT1 substrates in neurons and ﬁbroblasts may differ; alternatively,
other acyl-protein thioesterases might be differentially expressed in
these cell types. In this respect, the possibility that the cytosolic acyl-
protein thioesterase 1 [67] modulates TNF-induced apoptosis cannot
be ruled out. In addition, PPT1 is present in the synaptosomes and
synaptic vesicles of neurons, and in presynaptic terminals of axons
[45]. It is therefore possible that PPT1 also acts extracellularly in the
nervous system, and that a defect in this activity accounts for a
toxicity on neuronal cells. Finally, in contrast to the rather selective
defect of TNF-induced apoptosis we observed, the endoplasmic
reticulum and oxidative stresses seen in PPT1-deﬁcient neurons
[68–70] appear to be common manifestations of NCLs and lysosomal
storage disorders [71].
NCLs are diseases due to mutations in at least eight distinct genes.
Despite this genetic heterogeneity, they share common clinical
features that could suggest common pathogenic mechanisms. This is
why we assessed whether TNF-induced apoptosis was also altered in
CLN3 and CLN5-deﬁcient ﬁbroblasts. Emerging evidence indicates
that there exists some functional relationship between the different
CLN gene products [72,73]. However, in our study, murine Cln3−/−
and Cln5−/− ﬁbroblasts did not behave as their Cln1−/− counter-
parts, as they did not resist TNF-induced cell death. As to the
susceptibility to TNF of ﬁbroblasts with cathepsin D deﬁciency (a
defect underlying CLN10), discordant results have been reported
[13,74]. Thus, resistance to TNF-induced apoptosis may not be a
1257C. Tardy et al. / Biochimica et Biophysica Acta 1793 (2009) 1250–1258common pathogenic mechanism to all forms of NCL. Whereas the
mechanism of dysregulation of apoptosis in cells harboring a defect in
PPT1 activity might be indirect and still remains to be elucidated, it
appears that this protein thioesterase plays a key role in the regulation
of mammalian cell death. Interestingly, further indication that PPT1
has a prominent role in the regulation of cell death has been provided
in Drosophilawhere its increased expression dose-dependently led to
apoptosis of photoreceptors [75].
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